Related Experiment Videos
Effects of the Clara cell toxin, 4-ipomeanol, on pulmonary function in rats
Abstract:
The naturally occurring compound, 4-ipomeanol (IPO, 1-[3-furyl]-4-hydroxy-1-pentanone), selectively damages the nonciliated epithelial (Clara) cells of the terminal bronchioles. Because information is not available concerning functional changes in IPO-treated lungs, an investigation was undertaken to evaluate the in vivo pulmonary ventilatory, mechanical, and gas exchange functions of female Long-Evans rats 24 h after treatment with a single intraperitoneal dose of 1 or 5 mg IPO/kg body wt. A preliminary toxicity study established the 24-h LD50 for intraperitoneally administered IPO at 19 +/- 3 (SD) mg/kg. Significant increases in lung fluid occurred in animals treated with 15 mg IPO/kg, and histological evidence of pulmonary edema was observed in animals treated with 10 mg IPO/kg. Treatment of rats with 5 mg IPO/kg caused a significant decrease in tidal volume and a significant increase in respiratory rate and functional residual capacity-to-total lung capacity ratio (%). In rats treated with 1 mg IPO/kg, pulmonary functions were minimally affected. The functional changes observed in IPO-treated animals can be attributed to swelling and possible dysfunction of Clara cells, with subsequent alveolar interstitial edema and stimulation of juxtapulmonary capillary receptors, or to a direct effect of the toxin on respiratory control mechanisms.
Insights
4-ipomeanol (IPO) selectively damages lung Clara cells. Higher doses significantly impair ventilatory function, increasing respiratory rate and lung capacity, suggesting IPO
Area of Science:
- Toxicology
- Pulmonary Physiology
- Respiratory Medicine
Background:
- 4-ipomeanol (IPO) is a naturally occurring compound known to selectively damage lung Clara cells.
- Limited information exists regarding the functional consequences of IPO exposure on lung physiology.
- Understanding IPO's effects is crucial for assessing its toxicological impact on the respiratory system.
Purpose of the Study:
- To evaluate the in vivo pulmonary ventilatory, mechanical, and gas exchange functions following IPO treatment.
- To determine the dose-dependent effects of IPO on respiratory parameters in Long-Evans rats.
- To elucidate the mechanisms underlying IPO-induced pulmonary dysfunction.
Main Methods:
- Female Long-Evans rats were administered single intraperitoneal doses of 1 or 5 mg/kg body weight of IPO.
- Pulmonary function tests were conducted 24 hours post-treatment.
- A preliminary toxicity study determined the 24-hour LD50 for IPO.
Main Results:
- The 24-hour LD50 for IPO was established at 19 +/- 3 mg/kg.
- Doses of 10-15 mg/kg IPO caused pulmonary edema and increased lung fluid.
- Treatment with 5 mg/kg IPO resulted in decreased tidal volume, increased respiratory rate, and altered lung capacity ratios.
Conclusions:
- IPO exposure significantly alters pulmonary function in a dose-dependent manner.
- Observed functional changes are likely due to Clara cell damage, edema, and receptor stimulation.
- IPO poses a risk to respiratory health, necessitating further investigation into its toxicological profile.